

# OBSEVA SA CHF0.076923

ISIN: CH1260041939 WKN: 126004193 Asset Class: **Stock**

## Company

2024/05/03 17:33:01

Price

**0.00**

CHF

Difference  **-76.92%(0.00)**



## Contact Details

OBSEVA SA

Tel: +41-22-552-38-40

--

Fax: +

Chemin des Aulx, 12, Plan-les-Ouates

Web: <http://www.obseva.com>

1228 Genf

E-mail: [contact@obseva.ch](mailto:contact@obseva.ch)

## Company Profile

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2022		2021		2020	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	15,993,000		63,517,000		36,968,000	
<b>Common stock capital</b>		8,755,000		6,489,000		4,574,000
<b>Fixed assets</b>	551,000		25,474,000		28,479,000	
<b>Equity capital of a company</b>		8,483,000		32,339,000		8,354,000
<b>Cash and cash equivalents</b>	14,958,000		54,734,000		31,183,000	
<b>Accrued liabilities</b>		583,000		7,172,000		8,218,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		7,186,000		23,507,000		21,704,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		875,000		33,145,000		35,389,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		292,000		0		919,000
<b>Total assets</b>	16,544,000	16,544,000	88,991,000	88,991,000	65,447,000	65,447,000

## Balance notes

	2022	2021	2020
<b>Accounting standard</b>	IFRS	IFRS	IFRS
<b>Employees</b>	15	51	45
<b>Equity ratio</b>	51.28%	36.34%	12.76%
<b>Debt-equity ratio</b>	95.03%	175.18%	683.42%

## Others

	2022	2021	2020
<b>Tax Expense Rate</b>	-0.04%	-0.36%	-0.04%

# OBSEVA SA CHF0.076923

ISIN: CH1260041939

WKN: 126004193

Asset Class: Stock

## Income statement

	2022	2021	2020
Turnover	19,637,000	0	0
Net income	-29,879,000	-58,377,000	-82,966,000
EBIT	-18,745,248	-49,959,174	-72,384,448
Operating income before taxes	-29,868,000	-58,165,000	-82,932,000
Cash Flow	-23,146,000	-72,788,000	-73,087,000
Net interest income	-9,228,000	-3,156,000	-3,231,000
Research and development expenses	10,710,000	52,695,000	67,089,000
Income taxes	11,000	212,000	34,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	1,188,955	0	0

## Board of Directors

Luigi Marro	Member of the administrative board
Ernest Loumaye	Chairman of the administrative board

## Members of Management Board

Fabien de Ladonchamps	Chairman of Managing Board
-----------------------	----------------------------